Zylox-Tonbridge Medical Technology and GL Capital agreed to invest about HK$1.482 billion in LifeTech Scientific. The money buys newly issued LifeTech shares worth roughly 16.7 percent of the enlarged share capital. Both companies trade in Hong Kong.
The cash flows through GL Lighthouse Two Investment Limited, which Zylox-Tonbridge owns 60 percent of and funds to about HK$889 million. Lighthouse Two becomes LifeTech's largest single shareholder. In a linked trade, GL Capital subscribes for 39.8 million new Zylox-Tonbridge shares at HK$22 each, about 10.8 percent of that company's enlarged capital. The price is a 13.5 percent premium to the announcement day close.
Zylox-Tonbridge said it intends to pursue a merger with LifeTech and that the parties may buy more LifeTech shares. LifeTech, founded in 1999 in Shenzhen, sells left atrial appendage occluders and aortic stent graft systems. Zylox-Tonbridge sells peripheral devices under the Zylox brand and neurovascular devices under Tonbridge, and reports 69 NMPA approvals.
Cross-shareholding ahead of a merger lets both boards work out the combination without putting it to a vote on day one. It also sets a floor on price, since GL Capital paid a premium for its Zylox-Tonbridge stake.